The US President repeals Biden's 2023 executive order on AI safeguards, impacting healthcare and drug research. The rollback eases compliance for AI developers but raises concerns over risks of unsafe ...

The US Food and Drug Administration (FDA) is warning about the risk of a rare but serious allergic reaction with the medicine ...

US clinical-stage biotech ArriVent BioPharma has entered into an exclusive license agreement with Shanghai-based Lepu ...

Suzhou, China-based Ascentage Pharma revealed that it plans to raise $149 million by offering 7.3 million American Depositary ...

Privately-held US biopharma Bluejay Therapeutics has announced that its lead product candidate brelovitug—also known as BJT-778—has received US Food and Drug Administration Breakthrough Therapy ...

Shares of Coherus BioSciences rose 4.5% to $1.8 in pre-market activity after it released positive med-stage results for its ...

T-cell immunotherapy company Atara Biotherapeutics closed 8% lower on Tuesday, having lost 41% of its stock market value on ...

The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...

Icelandic drug discovery and development company Arctic Therapeutics has announced the successful closing of a 26.5 million ...

Kyverna Therapeutics appoints Naji Gehchan as CMO to advance KYV-101, its CD19-directed CAR-T therapy for autoimmune diseases ...

Spektus Pharma, a Quebec-based specialty pharma company developing therapeutics for the treatment of CNS disorders, has ...

The FDA issues a warning letter to Sanofi over manufacturing violations at its Massachusetts site, citing contamination and ...